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Abstract
Systematic analyses of the expression of angiogenic
regulators in cancer models should yield useful infor-
mation for the development of novel therapies for ma-
lignantgliomas. In thisstudy,weanalyzed tumorgrowth,
vascularization, and angiopoietin-2 (Ang2) expression
during the development of U-87 MG xenografts. We
found that tumoral angiogenesis in this model follows a
multistage process characterized by avascular, prolific
peripheral angiogenesis, and late vascular phases. On
day 4, we observed an area of central necrosis, a periph-
eral ring of Ang2-positive glioma cells, and reactive
Ang2-positive vascular structures in the tumor/brain
interface. When the tumor had developed a vascular
network, Ang2 was expressed only in peripheral vas-
cular structures. Because Ang2 expression was down-
modulated in the late stages of development, probably to
maintain a stable tumoral vasculature, we next studied
whether sustained Ang2 expression might impair vas-
cular development and, ultimately, tumor growth. Ang2
prevented the formation of capillary-like structures and
impaired angiogenesis in a chorioallantoic membrane
chicken model. Finally, we tested the effect of sustained
Ang2 expression on U-87 MG xenograft development.
Ang2 significantly prolonged the survival of intracranial
U-87 MG tumor–bearing animals. Examination of Ang2-
treated xenografts revealed areas of tumor necrosis and
vascular damage. We therefore conclude that deregu-
lated Ang2 expression during gliomagenesis hindered
successful angiogenesis and that therapies that sus-
tain Ang2 expression might be effective against malig-
nant gliomas.
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Introduction
Malignant gliomas, the most common subtype of primary
brain tumor, are aggressive and neurologically destructive.
Poor outcome is best exemplified by a median survival of
9 to 12 months in patients with glioblastoma multiforme
(GBM), the most aggressive form of glioma, despite maximum
treatment efforts [1]. More effective treatments for these tumors
now depend almost entirely on a better understanding of the
biology of these tumors. Thus, by delineating the molecular
events that occur during glioma formation, researchers should
be able to design therapies that target the multistage nature
of tumorigenesis.
One of the major pathophysiologic characteristics of malig-
nant gliomas—indeed of solid tumors in general—is their ability
to induce a robust angiogenic response, with GBMs being
one of the most vascularized tumors in humans [2]. If neo-
vascularization is prevented, tumor growth is dramatically im-
paired,with the tumor volume restricted to a few cubicmillimeters
[3]. Thus, agents that inhibit angiogenesis are particularly at-
tractive as a therapeutic option [4,5].
Animal models of cancer, including both traditional tumor
transplant models and newer genetically engineered mouse
models of cancer, have helped establish the causality of angio-
genesis [6–8] and have provided the means for assessing
antiangiogenic therapeutic strategies [6,9,10]. Implantation of
U-87 MG glioma cells into immunodeficient animals produces
solid intracerebral tumors, and the growth characteristics of
these tumors are reproducible. For such reason, U-87 MG is
one of the most frequently used models for testing therapies for
malignant gliomas [11]. However, comparatively little is known
about the chronology of angiogenesis in this model. In this
study, we therefore first characterized the tumor growth and
vascular development of the human glioma xenograft U-87 MG
in a nude mouse model. In particular, we focused on angio-
poietin-2 (Ang2) because of descriptive studies suggesting that
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it is a complex regulator of vascular remodeling that plays a
role in both vessel sprouting and vessel regression. This
concept of Ang2 as a destabilizing signal that causes vessels
to revert to a more plastic and tenuous state, which was
initially formulated based on observations in ovary remodel-
ing [12,13], is consistent with more recent data obtained from
transgenic mice [14]. In addition, in gliomas, Ang2 expres-
sion has been detected in coopted tumor vessels and in
areas of vessel regression during angiogenesis [7,8]. How-
ever, the function of Ang2 in glioma angiogenesis is still not
certain [15,16]. Based on observed spatial and temporal
expression patterns of Ang2, we then hypothesized that
sustained Ang2 expression could lead to impaired vascular-
ization and, ultimately, to impaired tumor growth. We thus
also tested the sustained expression of Ang2 in a U-87 MG
tumor–bearing nude mouse model.
Materials and Methods
Cell Lines and Culture Conditions
U-87 MG cells were obtained from the American Type Cul-
ture Collection (Manassas, VA) and maintained in Dulbecco’s
modified Eagle’s/F12 medium (1:1 vol/vol) supplemented
with 10% fetal bovine serum in a humidified atmosphere con-
taining 5% CO2 at 37jC. Human umbilical vein endothelial
cells (HUVECs; passages 2–7) were maintained as recom-
mended by the manufacturer (Clonetics, Walkersville, MD).
Animal Studies
To study tumor growth and the angiogenic pattern of U-87
MG xenografts, 5  105 U-87 MG cells were engrafted into
the caudate nuclei of athymic mice (4- to 6-week-old female
mice; Harlan-Sprague Dawley, Inc., Indianapolis, IN) using a
previously described guide-screw system [17]. Engrafted
animals were sacrificed 8 hours and 1, 4, 6, 12, 17, and
20 days after cell implantation (n = 3–4 per time point). The
animals were anesthetized before sacrifice; sacrifice was
performed by perfusing their hearts with 4% paraformal-
dehyde. The brains were incubated overnight in 4% para-
formaldehyde and then embedded in paraffin. The brains
were sectioned along the coronal plane to identify detectable
tumors and to prepare specimens for microscopic examina-
tion. Hematoxylin and eosin (H&E)–stained slides were
evaluated to look for evidence of tumors and to identify the
characteristics of tumors. The largest (a) and smallest (b) di-
ameters of the tumors were measured, and tumor volume
was calculated using the formula: 0.4ab2 [18].
To assess the anticancer effects of Ang2, U-87 MG cells
(5  105) were implanted in murine brains, and AdCMV,
AdAng2, or vehicle [phosphate-buffered saline (PBS)] was
administered locally (1.5  108 pfu) starting 3 days later and
continuing twice weekly for 3 weeks. Thus, animals were
treated with intratumoral injections of AdAng2, AdCMV, or
PBS starting on day 4 after cell implantation. Animals showing
generalized or localized symptoms of toxicity were sacrificed.
Surviving animals were sacrificed 115 days after cell implan-
tation. Animal studies were performed in veterinary facilities
at The University of Texas M. D. Anderson Cancer Center
(Houston, TX), in accordance with institutional guidelines.
Immunohistochemical Analysis
Paraffin-embedded sections of mouse brain tumor were
deparaffinized, rehydrated, and equilibrated in PBS. After
antigen retrieval, the slides were incubated with 0.3% H2O2
in methanol for 30 minutes to quench endogenous peroxi-
dase activity. Then, blocked sectionswere incubated overnight
at 4jCwith the following primary antibodies: anti–proliferating
cell nuclear antigen (PCNA) (PC-10, diluted 1:500; Dako Co.,
Carpinteria, CA), anti–smooth muscle actin (SMA) (IA4, di-
luted 1:500; Dako Co.), anti–von Willebrand factor (factor
VIII–related antigen; clone mo812, diluted 1:500; Dako Co.),
anti-nestin (MAB353, diluted 1:100; Chemicon, Temecula,
CA), and anti-Ang2 (N-18, diluted 1:200; Santa Cruz Bio-
technology, Santa Cruz, CA). All slides were subsequently
washed for 5 minutes in PBS with 0.1% Tween-20 and in-
cubated with secondary antibodies for 30 minutes. Bound
antibodies were detected by the avidin–biotin–peroxidase
methodwith anABCElite kit (Vector Laboratories, Burlingame,
CA). Staining was performed with diaminobenzidine Stable
DAB (Research Genetics, Carlsbad, CA) or Stable Fast red
(Research Genetics). Sections were counterstained with he-
matoxylin (Sigma Chemical Co., St. Louis, MO) and mounted
under glass coverslips with Immu-mount (ThermoShandon,
Pittsburgh, PA). For factor VIII/nestin immunofluorescence
double staining, blocked sections were incubated with anti–
factor VIII and anti-nestin antibodies overnight at 4jC and
then with secondary Texas red–conjugated antibody (T-2767;
Molecular Probes, Eugene, OR) or fluorescein isothiocyanate
(FITC)–conjugated antibody (F-2761; Molecular Probes) for
1 hour at room temperature. After washing, mounted slides
were analyzed by fluorescent microscopy (Zeiss Axiovert
200; Carl Zeiss MicroImaging, Inc., Thornwood, NY), with
separate filters used for each fluorochrome. Images were
obtained using the software package XCAP-Lite, Version 2.1
(EPIX, Inc., Buffalo Grove, IL).
Quantification of Microvessel Density (MVD)
Areas containing the most microvessels (or tumor ‘‘hot
spots’’) were identified by examining the sections with a light
microscope at low magnification (original magnification, 40
and 100), as previously described [5,19]. Then, the indi-
vidually stained microvessels in these areas were counted
at200magnification over a square grid that corresponded to
a field size of 0.5 mm2. Large microvessels and single brown-
stained endothelial cells that were clearly separate from the
microvessels were included in the microvessel count; branch-
ing structures were counted as one vessel, unless there was a
break in the continuity of the vessel, in which case it was
counted as two distinct vessels. The mean number of micro-
vessels counted in five fields was used for analyses.
Adenoviral Constructs
To create the Ang2 adenoviral construct, Ang2 cDNA
(1504 bp; GenBank accession no. AF 004327) was amplified
by reverse transcription–polymerase chain reaction using
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the primers 5V-TACTGAAGAAAGAATGTGG-3V (forward)
and 5V-TTAGAAATCTGCTGGTCGG-3V (backward) from
HUVECs. Subsequently, Ang2 cDNA was cloned into an ex-
pression cassette (CMV promoter, SV40pA) in the shuttle
adenoviral vector, pDE1sp1A (Microbix Biosystems, Toronto,
Ontario, Canada). Then, the replication-deficient adenovirus
vector containing the human Ang2 cDNA (AdAng2) was con-
structed and characterized as described previously [20].
AdCMV, an empty adenovirus vector containing only a Cyto-
megalovirus promoter and a simian virus 40 polyadenylation
signal, was used as control [21]. Culture infections were
performed as described previously [21].
Western Blot Analysis
U-87 MG cells (2.5  105 cells) were seeded in 60-mm
dishes. After 1 day, cells were infected with AdCMV or
AdAng2 at the indicated multiplicities of infection (MOI) and
were incubated for 2 days. Then cells were washed twice,
and 2 ml of serum-free medium was added. After 1 day,
the conditioned medium was collected, cells were lysed, and
15 mg of secreted proteins or 30 mg of whole-cell lysates was
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and electroblotted onto a nitrocellulose
membrane. Ang2 expression was determined by immuno-
blotting with anti-Ang2 antibody (C-20; Santa Cruz Bio-
technology). The membranes were developed using an
enhanced chemiluminescence reagent (Amersham Corp.,
Arlington Heights, IL).
Cell Viability Assay
U-87 MG cells were first mock-treated or treated with
AdCMV or AdAng2 at an MOI = 100. Three days later, the
apoptotic cell population was determined by staining with
Annexin V–FITC (BD Biosciences, San Jose, CA) and pro-
pidium iodide (PI), as recommended by the manufacturer.
Annexin V–FITC–stained and PI-stained cells were quanti-
fied with a FACScalibur (BD Biosciences).
Tube Formation Assay
HUVECs (2  104) were seeded on Matrigel-coated
96-well plates (50 ml, 10 mg/ml; BD Biosciences) and grown
for 16 hours, in conditioned medium collected from U-87 MG
cells treated with AdAng2, AdCMV, 0.1% bovine serum
albumin (BSA), or recombinant Ang2 (rAng2; 200 and
400 ng/ml; R&D Systems, Minneapolis, MN). Morphologic
cellular changes were visualized with a Zeiss Axiovert
200 microscope and photographed at 100 magnification
by XCAP-Lite, Version 2.1 (EPIX, Inc.).
Chorioallontoic Membrane (CAM) of Chick Embryo Assay
CAM assay was performed as described elsewhere [22],
with slight modifications. Briefly, fertilized chick eggs
(SPAFAS; Charles River Laboratory, Wilmington, MA) were
incubated at 37jC and 55% humidity for 7 days. Filter disks
(6 mm in diameter) were coated with cortisone acetate in
absolute ethanol (3 mg/ml). CAMs were treated locally with
filter disks saturated with a solution containing BSA (0.1%) or
rAng2 (200 and 400 ng/ml). The filter was placed on the CAM
in a region with the lowest density of blood vessels and in the
vicinity of a large vessel as a reference point. Angiogenesis
was monitored by photographs taken starting 3 days after
treatment. Images were captured using an Olympus stereo-
microscope (SZx12; Olympus, Melville, NY) and Spot basic
software (Diagnostic Instruments, Inc., Sterling Heights, MI).
Statistical Analyses
Experimental results obtained in the CAM assay were
statistically evaluated using Fisher’s exact test. Survival
was assessed by plotting survival curves according to the
Kaplan-Meier method, and comparisons were performed
using the log-rank test.
Results
Vascular Development and Tumor Kinetics
To delineate the tumor growth and angiogenic kinetics of
U-87 MG intracranial xenografts, we performed a time point
analysis of this model after implanting those cells into the
brain of nude mice. Eight hours after cell implantation, the
cells were grouped together, and there was no evidence of
modifications to surrounding host vessels (Figure 1A). At this
time, more than 90% of implanted cells expressed PCNA,
indicating that the implanted U-87 MG cells proliferated
actively (Figure 1B). Twenty-four hours after cell implanta-
tion, the cells were still clustered together as a small mass,
but with a center displaying signs of cell death compatible
with karyorrhexis (data not shown). At this time, we also ob-
served engorged vessels in the normal parenchyma of mice
proximal to the tumor. Interestingly, these vessels were posi-
tive for SMA, indicating the existence of reactive pericytes
(Figure 1C). By day 4, the tumors had grown to a mean vol-
ume of 0.37 mm3 and contained an area of central necrosis
surrounded by a mass of cells with a very low MVD (Fig-
ure 1D, Table 1). The vessels in the host parenchyma
surrounding the tumor displayed changes in morphology,
including an enlarged diameter and a disorganized structure
(Figure 1, E and F ). Some of the vessels interacted physi-
cally with peripheral tumor cells. This pattern suggests that
the mouse vessels had extended into human tumor cells
through the process of cooption and/or new branching.
Staining for SMA was intense in peritumoral vessels, and
the staining pattern highlighted an important alteration in
their architecture, showing disorganized structures that were
consistent with vessels undergoing remodeling processes
(Figure 1,D and E ). On day 6 after implantation, although the
tumors were small (a mean of about 1 mm3), the MVD curve
profile was within its exponential phase (Table 1). Twelve
days after implantation, the tumors consisted of sphere-like
masses of cells (volume, 31 mm3), along with intratumoral
vessels (MVD mean, 37.55 vessels/0.5 mm2; Table 1,
Figure 1G). At this time, we did not find large areas of necrosis
or foci of necrosis with pseudopalisading. In addition, the
vessels were numerous, large, distorted, and SMA-positive
(Figure 1, G and H ). Tumor limits were clearly defined, and
cancer cells did not exhibit an invasive pattern into host
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tissues, as seen earlier. The tumor volume at 20 days after
implantation reached around 100 mm3 (Table 1). At this time,
the tumors also exhibited a high mean MVD (62 vessels/
0.5 mm2) plus a highly proliferative pattern without areas of
necrosis (Figure 1, I and J ). All mice showed signs of toxicity
by day 30, which correlated with the development of an
expansive mass, causing extreme brain compression.
Thus, although the U-87 MG intracranial tumors hardly
grew initially while they were avascular structures, as soon
as 1 day after implantation and definitely by day 4, changes
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in the host vessels were evident; these included the exis-
tence of engorged SMA-positive vascular structures in the
periphery of the xenograft. In the case of U-87 MG tumors,
this was accompanied by central necrosis that disappeared
by 1 week after implantation when intratumoral angio-
genesis became evident. After this, increased MVD was
associated with exponential tumor growth and with a de-
crease in induced angiogenesis within the host and in the
tumor periphery.
Ang2 Expression Pattern during Glioma Development
Because Ang2 is considered a complex regulator of
vascular remodeling, we studied the temporal and spatial
expressions of Ang2 during early angiogenesis (before
day 4 after cell implantation) and later when intratumoral
angiogenesis had become established and peripheral angio-
genesis had become weaker (12–20 days after cell implan-
tation). We found that, during the early stage when the host
vessels were being coopted, the inner regions of the tumor
did not express Ang2. However, Ang2 was highly expressed
in the cytoplasm of most glioma cells within the vicinity of
normal tissues (Figure 2A). This zone of expression of Ang2
was approximately 10 cell layers thick, covered the entire
the tumor, and engulfed reactive vascular structures that
had developed in the border between the tumor and the
normal brain. Positive Ang2 staining was also seen in a few
isolated cells in the normal brain zone, suggesting the pres-
ence of tumor-infiltrative cells. Weaker Ang2 expression
was also observed in the cellular components of the reactive
vessels surrounding the tumor (Figure 2A). This well-defined
distribution of Ang2 expression suggested a role for Ang2
in the cooption of vessels. However, with tumor growth,
the pattern of expression of Ang2 changed drastically. Thus,
by 11 days after tumor cell implantation, Ang2 expression
was dramatically reduced in the tumor cells, such that the
tumor had become an Ang2-negative mass. Thus, Ang2
does not seem to be produced in high amounts during the
exponential phase of tumor growth. Although we hardly
detected Ang2 expression within the vascular component
at the center of the tumor, which by now was already well
developed, we did observe vascular structures that were
weakly positive for Ang2 at the tumor edge (Figure 2, B and
C). These vessels were, in general, enlarged. Collectively,
these observations suggest that high Ang2 expression is
required during the early stages of tumor development but
that Ang2 is downmodulated once the vascular structure of
the tumor has been developed.
Because nestin is a marker for proliferative endothelium
in gliomas [23], we next examined whether there was tem-
poral and spatial parallelism in the expression of nestin
and Ang2. First, we confirmed that nestin was expressed in
tumoral vessels in the U-87 MG xenograft model. In these
experiments, we performed double immunofluorescence for
factor VIII and nestin in a 20-day xenograft. As expected,
most of the vascular structures identified with phase-contrast
studies were positive for both markers (Figure 2, D and E ).
Then, we examined the expression of nestin during U-87 MG
tumor development. In the early angiogenic phase, nestin
was clearly expressed in vascular structures surrounding
the tumor (Figure 2F ). In fact, nestin expression was more
evident and frequent in vascular structures at this time of
tumor development than was Ang2. Although nestin was
also detected in scattered glioma cells, it assumed no spe-
cific pattern and in no way assumed the ring-like distribution
seen for Ang2 in the tumor. Therefore, in the early stages of
tumor development, nestin expression was more intense in
the vessels than in the glioma cells; therefore, it did not com-
pletely colocalize with Ang2. The differences in the expres-
sion between the two proteins were more marked in the late
stages of tumor development. Thus, although Ang2 expres-
sion in the glial or the vascular component of the tumor faded
in the late stages of tumor development (> 11 days after cell
implantation), nestin was widely expressed in intratumoral
vessels and in scattered cancer cells (Figure 2G).
Together, our results showed that Ang2 is over-
expressed early in angiogenesis, not only in vascular struc-
tures [7,8,24,25] but also in the tumor cells, specifically in the
periphery, where vascular cooption takes place. Further-
more, our finding that Ang2 and nestin expressions are not
correlated in advanced tumors could indicate that, although
Table 1. Tumor Growth Kinetics and MVD Analyses of U-87 MG Xenografts.
Time after n Volume (mm3) MVD (vessels/0.5 mm2)
Implantation
Mean SD Mean SD
8 hr 3 0.03 0.01 0 0
1 day 4 0.04 0.01 0.05 0.10
4 days 4 0.37 0.08 6.65 0.68
6 days 3 1.04 0.17 18.50 3.09
12 days 4 31.06 7.65 37.55 2.68
17 days 3 62.30 5.93 43.20 4.28
20 days 4 99.03 7.74 62.45 7.80
Figure 1. Vascular development of the U-87MG intracranial animal model. Examination of implanted U-87MG cells at different time points of tumor growth. (A and B)
A group of U-87 MG tumor cells 8 hours after implantation in an H&E–stained section (A) and in a PCNA-immunostained section (B) showing proliferation (PCNA-
positive, DAB staining; original magnification, 100). (C) Implanted cells on day 1. Note the incipient hyperplasia of vessels near the tumor interface that stained
positive for SMA (arrows) (DAB staining; original magnification, 400). (D–F) U-87 intracranial xenograft on day 4 after implantation. A central area of necrosis
(indicated by asterisk) and SMA-immunoreactive host vessels establishing intimate contact in the periphery of the tumor. Note the highly disorganized structure
(arrows in D) (DAB staining; original magnification, 100). In a close-up view of the tumor/normal brain interface, we observed numerous SMA-positive hyper-
vascular structures (arrows in E) (DAB staining; original magnification,400). (F) Note the presence of reactive vessels (arrows) from the host near the tumor and in
the tumor periphery (H&E; original magnification, 400). (G and H) U-87 MG xenograft on day 12. (G) H&E–stained section showing high microvascular density
with engorged structures (original magnification, 400). (H) Intratumoral vessels (arrowheads) that were positive for anti-SMA antibody (DAB staining; original
magnification, 400). (I and J) U-87 MG xenograft 20 days after cell implantation. (I) Staining with anti – factor VIII antibody showed a highly vascularized tumor
(Stable Fast red staining; original magnification, 400) (J) PCNA immunoreactivity was seen in most of the neoplastic glial cells (DAB staining; original magnifica-
tion, 400). T, tumor; NB, normal brain.
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some proliferative endothelial events occur in vessels at
this stage, Ang2-mediated activity is not required or needs
to be downmodulated for a stabilized intratumoral vascular
network to be maintained.
Ang2 Induces the Regression of Tubular Structures
of Vessels In Vitro
Based on the bimodal pattern of expression of Ang2
during U-87 MG tumor development, we hypothesized that
modifying the Ang2 expression profile would impair vascu-
larization and subsequent tumor growth. To test this possi-
bility, we first constructed a replication-deficient adenovirus
carrying the full-length wild-type Ang2 cDNA, AdAng2. We
then tested the efficacy of this vector in transducing Ang2 by
treating U-87 MG cells with AdAng2 at different doses and
then by performing Western blot analysis to determine the
expression of Ang2 in both the whole-cell lysate and the
conditioned medium. This showed that exogenous Ang2 was
expressed in a dose-dependent fashion and was secreted
into the extracellular milieu, mimicking the trafficking of the
endogenous protein (Figure 3A) without significantly modi-
fying the viability of the cultures (Figure 3B).
To investigate the effect of Ang2 overexpression on vessel
formation, we first performed an in vitro tube formation assay.
HUVECs cultured on Matrigel formed tube-like structures
within 16 hours. When endothelial cells were exposed to
conditioned media from AdAng2-treated U-87 MG cells, we
observed the production of foreshortened and severely bro-
ken tubes (Figure 3C). Of importance, these findings were
similar to those for HUVECs exposed to rAng2 (200 and
400 ng/ml). As expected, as with untreated cells, HUVECs
exposed to the conditioned media from U-87 MG cells
treatedwith AdCMVorBSA formed tube-like structureswithin
16 hours of treatment.
Ang2 Impairs Angiogenesis In Vivo
Using a CAM chicken model system, we next assessed
whether the Ang2-induced modifications of the phenotype of
endothelial cells interfered with angiogenesis in vivo. This
showed that Ang2 dramatically decreased newly sprouting
angiogenic vessels and caused them to assume a ‘‘branch-
less’’ pattern by 72 hours of treatment without any signs of
hemorrhage and with no egg lethality (Figure 3D). In par-
ticular, angiogenesis was impaired in 73.3% and 76.9% of
Ang2-treated CAMs at a dose of 200 and 400 ng/ml, respec-
tively (Figure 3D). Together, our in vitro and in vivo results
showed that, when Ang2 expression is sustained, Ang2 acts
as an antiangiogenic molecule by disturbing the necessary
organization of endothelial cells such that new branches
cannot form during angiogenesis. Moreover, the fact that
no signs of hemorrhage were observed indicates that the
overexpression of Ang2 does not result in detectable disrup-
tion of already formed vessels.
Sustained Expression of Ang2 Induces Tumor Inhibition
We next examined the effects of sustained Ang2 expres-
sion on pre-established intracranial glioma xenografts.
Thus, animals were treated with intratumoral injections of
Figure 2. Expression pattern of Ang2 and nestin during U-87 MG xenograft development. (A–C) Ang2 expression in U-87 MG intracranial xenografts on day 4 (A),
day 11 (B), and day 20 (C) after cell implantation. At an early time point, Ang2 was overexpressed in glial cells at the tumoral edge (double-headed arrow) and in
vascular structures (arrows) in the tumor/normal brain interface (DAB staining; original magnification, 100). However, on days 11 and 20, Ang2 expression was
detectable mainly in some vessels (arrows) in the periphery of the tumor (DAB staining; original magnification, 400). (D and E) Double immunofluorescence
studies using anti – factor VIII and anti-nestin antibodies indicate that nestin is expressed in vascular structures on day 20 after implantation (original magnification,
400). (F and G) Nestin expression in U-87 MG intracranial xenografts on day 4 (F) and day 20 (G) after cell implantation. Nestin is overexpressed in host vessels
at the tumoral edge (double-headed arrow) and in host vessels during early intense angiogenesis (DAB staining; original magnification, 100). After vessel
cooption, nestin is expressed by intratumoral vessels (DAB staining; original magnification, 400). T, tumor; NB, normal brain.
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AdAng2, AdCMV, or PBS starting on day 4 after cell im-
plantation. The median survival was 28 to 29 days in the
control groups, and all these animals died by day 32. In
contrast, treatment with AdAng2 significantly prolonged
the survival of U-87 MG tumor–bearing animals (median
overall survival, 48 days) compared with control-treated
animals (P = .0003; Figure 4A).
To determine the antitumoral effects of Ang2, we sacrificed
two animals in every group 10 days after cell implantation. At
that time, as expected, the brains of control animals with
adenoviral vector–treated glioma xenografts showed hyper-
cellular, highly vascularized tumors with no areas of necrosis.
There was also a developed vascular network, predominantly
near the tumor interface, as shown by immunostaining using
Figure 3. Ang2 inhibits angiogenesis in vitro and in vivo. (A) Transduction efficiency of AdAng2. As shown by Western blot analysis, exogenous Ang2 was
expressed in a dose-dependent manner in both the whole-cell lysate (WCL) and the conditioned medium (CM) of Ang2-treated U-87 MG cells. Actin expression
was used as loading control. (B) Viability analysis of AdAng2-treated U-87 MG cells. Apoptotic populations of U-87 MG cells were quantified 3 days after infection
with AdAng2 or AdCMV (MOI = 100) by Annexin V and PI staining and by FACS analysis. The percentages of cells in the early stage [Annexin V (+)/PI ()] and in
the late stage of apoptosis or cell death [Annexin V (+)/PI (+)] are shown. (C) Inhibition of tube formation of endothelial cells by Ang2. HUVECs plated in Matrigel-
coated dishes were incubated with the conditioned medium from U-87 MG cells previously treated with AdAng2 (Ang2), AdCMV (CMV), rAng2 (400 ng/ml), or BSA
(as control) (MOI = 100). Ang2 expression resulted in drastically disrupted capillary-like structures in vitro. Micrographs of typical fields illustrate HUVEC tube
formation under the influence of several different treatments. (D) Inhibitory effect of Ang2 on the capillary plexus of a CAM system. En face images of developing
CAMs treated with filter disks coated with BSA (0.1%) or Ang2 (200 or 400 ng/ml). Normal vascular distribution was observed in CAMs treated with BSA. Ang2
diminished the capillary network. This Ang2-mediated inhibition of angiogenesis in the CAM assay was quantified in terms of the total number of eggs and the
number of eggs that exhibited inhibition of angiogenesis (table in the figure). For the comparison of Ang2-treated CAMs and control-treated CAMs, P values were
determined by Fisher’s exact test.
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anti– factor VIII antibody (Figure 4B). In AdAng2-treated
xenografts, however, we observed large areas of necrosis,
karyorrhexis, and vascular damage, as revealed by varying
degrees of fibrinoid necrosis. Vascular fibrinoid necrosis
wasmore predominant at the center of the tumor, correspond-
ing to the most intense areas of tumor necrosis (Figure 4B).
Factor VIII staining also showed a disorganized vascular net-
work in the periphery of the tumor, in conjunction with ex-
tensive avascular areas (Figure 4B). These data were in
accordance with the findings from the in vitro tube formation
assay and the CAM model experiments, thus collectively
indicating that the induction and successful branching of blood
vessels were largely inhibited in the tumor interface region of
Ang2-treated tumors.
Discussion
Our analysis of angiogenesis and the growth characteristics
of U-87 MG human glioma xenografts intracranially im-
planted in nude mice showed that angiogenesis was ac-
complished in a stepwise fashion, consisting first of vessel
development and then of intratumoral vessel network main-
tenance. One particularly notable finding was the observa-
tion that Ang2 expression is detected not only in vascular
structures but also in glioma cells. This observable fact
happens early in tumor development, and its expression is
downmodulated and largely restricted to vascular structures
during the vascular phase of tumor growth, which suggests
that the sustained expression of Ang2 might serve as an
antitumor strategy. As a proof of principle of this possible
effect of Ang2 on this model, we treated U-87 MG tumors
with Ang2 during the intermediate and advanced stages of
vascular formation. This modification in the pattern of Ang2
expression induced vascular instability and inhibited tumor
growth, which resulted in the prolonged survival of U-87
MG–bearing animals.
Currently there are several well-characterized syngeneic
models of gliomas. Of these, themost frequently used are the
rat C6 [7] and mouse GL261 [8] models. Similar to the
nonsyngeneic U-87 MG model that we studied here, tumor
growth in these models results in the death of animals from a
mass effect, and disease progression is highly reproducible
[17]. However, thesemodels differ from theU-87MGmodel in
several ways (Figure 5). One is that theC6 andGL261 tumors
start off as parasitic small tumors around pre-existing ves-
sels, although the cooption of host tissue vessels is also ob-
served [7,8,26]. Robust angiogenesis develops within days
in the U-87MGmodel, and within weeks in the C6 andGL261
models. Therefore, it would seem that angiogenesis is
more effective in the U-87 MG model than in the rodent
models, circumventing the noteworthy hypoxia and necrosis
that occur concomitantly with vessel regression in the C6 and
GL261 models. Although the models discussed here seem
to differ partially in regard to the chronology of angiogenesis
and the temporal and spatial expressions of Ang2, a similar
rationale for the observed pattern of Ang2 expression applies
to all, in that the expression of Ang2 precedes or coincides
with tumor necrosis and vascular remodeling. Thus, in the
U-87 MG model, Ang2 is expressed in the vicinity of normal
tissues during the early vascular (cooption phase) stage of
the tumor. The expression of Ang2 at this time could allow
for vascular destabilization and remodeling [7,8], leading to
the branching of host vessels, which allows them to infiltrate
the incipient tumor mass. Later low levels of Ang2 expression
in the U-87 MG model are consistent with the lack of tu-
moral necrosis resulting from devastating vessel regression
and with a decrease in peripheral angiogenesis. The genetic
dissimilarity between human and rodent cancer cells, as well
as the different cross-talk signaling between rodent–rodent
and rodent–human tissues, might help explain partially the
Figure 4. The sustained expression of Ang2 prolongs the survival of human
glioma–bearing animals. (A) Kaplan-Meier survival curves of nude mice
bearing U-87 MG intracranial xenografts treated (3 days after cell implanta-
tion) with AdAng2 (Ang2), AdCMV (CMV), or PBS (twice a week for a total of
3 weeks) using a guide-screw system. P values were determined by means of
a log rank test and represent survival comparisons of AdAng2-treated mice
and AdCMV-treated mice. (B) High-magnification cross-sectional views of
H&E–stained sections of AdAng2- and AdCMV-treated intracranial tumors
10 days after cell implantation (upper panel, arrow) (original magnification,
400; note the structure of the vessel within the tumor). Extensive areas of
necrosis were found in both tumor cells (karyorrhexis; asterisk) and vessels
within the tumor (fibrinoid hyalinosis; arrowheads) in the Ang2-treated xeno-
grafts. Factor VIII staining revealed disruption of the vascular network and
extensive avascular areas in the tumor/normal brain interface of Ang2-treated
mice (bottom panel) (original magnification,100). T, tumor; NB, normal brain.
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differences in the chronology of angiogenesis seen among
animal models.
Several reports support the expression of Ang2 as a
unique feature of vascular structures [7,8,24,25]. None-
theless, our findings are consistent with those of others,
wherein the expression of Ang2 is observed also in cancer
cells [27,28]. The high expression of Ang2 by the neoplastic
glial compartment of U-87 MG xenografts, specifically in the
periphery of the tumor, suggests at least a paracrine func-
tion for Ang2 in the regulation of initial angiogenesis, which
could be unnecessary or even disadvantageous in the latter
stages of vascular maintenance.
Based on our hypothesis that the sustained expression of
Ang2 could promote vessel involution and tumor necrosis,
we developed a novel therapeutic strategy that would main-
tain high intratumoral levels of Ang2 throughout the evolu-
tion of U-87 MG xenografts. Our data indicated that the
resultant sustained expression of Ang2 inhibited tumor
growth due, at least, to impaired vascularization. These data
were confirmed by our data from the tube formation assay
and the CAM chicken embryo assay. Moreover, these re-
sults dramatically buttress the belief that Ang2 expression
in the intermediate phases of the C6 and GL216 models
is responsible for vessel involution [7,8]. In line with this,
Machein et al. [16] reported recently that the implantation of
Ang2-transfected mouse cells into the brains of animals re-
sulted in smaller tumors with aberrant vascularity. Strong
evidence supporting the antiangiogenic role of Ang2 also
comes from Ang2-overexpressing transgenic animal mod-
els, which showed widespread vessel discontinuity and
embryonic lethality [12]. However, another study in which
an intracranial animal model was used showed that glioma
cells overexpressing Ang2 displayed an invasive pheno-
type [15]. It is certainly possible that different relative levels
of Ang2 could lead to very different outcomes, as suggested
in previous descriptive reports and by studies in transgenic
mice in which the expression of Ang2 and/or vascular
endothelial growth factor was induced in the choroidal and
retinal circulations [29,30]. This varying expression thresh-
old might explain the different results obtained for the clonal
selection of cells expressing Ang2 [15].
In summary, we have identified the chronology of angio-
genesis and Ang2 expression in the commonly used U-87
MG model. Our data indicate that angiogenesis in the U-87
MG model differs from that in the syngeneic C6 and GL261
glioma models. We also showed that continuous expression
of Ang2 results in vessel disorganization and inadequate
angiogenesis, hence inhibiting tumor growth. Before Ang2-
based antiglioma therapies are implemented, studies should
be performed to further clarify the controversial role of Ang2
in tumor angiogenesis and invasion.
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